RE:RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
The end to Biotech’s bear market – and early recovery – explained
Portfolio Manager Andy Acker joins a panel discussion during the Accelerating Bio-Innovation 2024 Conference in Cambridge, England. During the panel, hosted by Terry Coyne, chief financial officer at Royalty Pharma, and joined by investors Rajiv Kaul and Phill Gross, Mr. Acker explains the factors that caused one of the worst drawdowns on record in biotech starting in 2021, and why he believes the selling has largely ended.
https://www.janushenderson.com/corporate/article/biotechs-bear-market-and-early-recovery-explained/